ENTX Entera Bio Ltd.

NEUTRAL Impact: 3/10 S-3
Horizon weeks Filed May 8, 2026 Processed 1mo ago SEC 0001178913-26-002460
Shelf registration — potential dilution
Latest settled — T+5d ⚠ clustered
ENTX ▲ +5.13% at T+5d
NEUTRAL call ✓ call won +5.13% · α vs SPY +5.21% · entry $1.17 → $1.23
Next anchor: T+20d due 7d ago
Last close $1.23 (close Jun 12) · +5.13% from $1.17 entry
Entry anchored
May 8, 03:24 PM ET
via Databento tick
T+1d
0.00%
call 0.00% · α +0.14%
$1.17
settled 5w ago
T+5d
+5.13%
call +5.13% · α +5.21%
$1.23
settled 4w ago
T+20d
call — · α —
due 7d ago
T+60d
call — · α —
in 7w

Price Chart

Loading chart...

Executive Summary

Entera Bio filed an S-3 to register 19.6M ordinary shares for resale by BVF entities, issued in a $10M private placement on April 2, 2026. The company will not receive proceeds from resales but could gain up to $14.5M from warrant exercises. The filing is a contractual obligation, not a new capital raise, and follows a Q1 earnings beat.

Actionable Insight

The S-3 is a standard resale registration with no immediate trading impact. Monitor for warrant exercises, which would provide additional cash runway. The stock may face overhang from potential selling by BVF, but the private placement already signaled insider commitment.

Key Facts

  • Registered up to 19,569,472 ordinary shares for resale by BVF selling shareholders, including shares and warrants from the April 2026 private placement.
  • Private placement raised ~$10M at $1.2775 per unit (1 share + 1.5 warrants).
  • Warrants have exercise price of $1.24 per share, exercisable after 6 months (Oct 2026), expiring in 5 years.
  • If all ordinary share warrants are cash-exercised, Entera could receive ~$14.5M additional proceeds.
  • Q1 2026 net loss of $3.5M ($-0.07/share) beat consensus by 12.5%.
  • Cash and cash equivalents were $13.6M as of March 31, 2026, excluding the $10M private placement closed April 2.
  • Company plans to use proceeds for Phase 3 EB613 osteoporosis study and working capital.

Financial Impact

Potential dilution of up to 39.8% if all registered shares are issued (19.6M vs 49.2M outstanding), but these shares are already outstanding or issuable from the private placement; the registration does not change economic dilution.

dilution

Risk Factors

  • Potential overhang from resale of 19.6M shares by BVF entities.
  • Geopolitical risks from operations in Israel amid regional conflicts.
  • Clinical trial risks for EB613 Phase 3 and other pipeline candidates.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (7 analysts)

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001178913-26-002460
Exhibit: ex107.htm0001178913-26-002460
Exhibit: exhibit_5-1.htm0001178913-26-002460
Exhibit: exhibit_23-1.htm0001178913-26-002460
Document: 0001178913-26-002460-index-headers.html0001178913-26-002460
Document: 0001178913-26-002460-index.html0001178913-26-002460
Document: 0001178913-26-002460.txt0001178913-26-002460
9 reports for ENTX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ENTX — sortable, filterable
Type Now
May 28, 2026
17d ago
Press Release
BULLISH ★ 6/10
$1.22 $1.22· 0.00%▲ +0.05%$1.23 (+0.82%)
May 18, 2026
28d ago
EFFECT
NEUTRAL ★ 3/10
$1.23 $1.21▼ −1.63%▼ −3.24%$1.23 (+0.00%)
May 8, 2026
5w ago
S-3
NEUTRAL ★ 3/10
$1.17 $1.23▲ +5.13%▲ +5.21%$1.23 (+5.13%)
May 8, 2026
5w ago
8-K
NEUTRAL ★ 5/10
$1.17 $1.23▲ +5.13%▲ +5.21%$1.23 (+5.13%)
Apr 14, 2026
8w ago
Press Release
NEUTRAL ★ 2/10
$1.13 $1.19▲ +5.31%▲ +3.92%$1.23 (+8.85%)
Apr 3, 2026
10w ago
8-K
BEARISH ★ 6/10
$1.19 $1.12▲ +5.88%▲ +10.02%$1.23 (−3.36%)
Apr 2, 2026
10w ago
Press Release
MIXED ★ 6/10
$1.26 $1.15▼ −8.73%▼ −12.35%$1.23 (−2.38%)
Mar 27, 2026
11w ago
Press Release
MIXED ★ 5/10
$1.00 $1.17▲ +17.00%▲ +12.70%$1.23 (+23.00%)
Mar 5, 2026
14w ago
Insider Cluster
NEUTRAL ★ 4/10
$1.23 $1.32▲ +7.32%▲ +9.55%$1.23 (+0.00%)
Showing 9 of 9

US Market Status

Market Closed — Opens in 3h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access